UCL trial shows abiraterone may halve death risk in high‑risk localized prostate cancer
Medical Xpress reports that prostate cancer is the most common cancer in men, affecting more than 1 million men worldwide in 2013 . Medical Xpress notes that treating the disease more aggressively than necessary is linked to increased side effects and poorer quality of life . Medical Xpress says doctors must balance identifying patients who need intensive treatment with those who may do well with less aggressive therapy . Medical Xpress reports that at a major cancer conference in Madrid, a University College London team presented STAMPEDE trial results showing that adding the hormone therapy abiraterone to standard treatment for men with high‑risk, localized prostate cancer could halve the risk of death . Medical Xpress adds that the same trial indicated the addition also slowed overall disease progression .
Why it matters. Medical Xpress indicates that the findings could reduce mortality and slow disease progression for men with high‑risk localized prostate cancer .